

**North of Tyne
Area Prescribing Committee**

www.northoftyneapc.nhs.uk

**Tuesday 12th March 2013.
Room 3, Northumbria House, Unit 7/8 Silver Fox Way, Cobalt
Business Park.
The meeting will start at 12:30pm**

AGENDA

1. Apologies for absence
2. Declarations of interest
 - Relevant declarations
3. Appeals against previous decisions
 - Cefixime
 - Flutiform

Enclosed with agenda
4. Minutes and decision summary from the meeting held on 8/1/13

Email 21/1/13
5. Matters arising/actions from previous meeting
 - None
6. Report from the Formulary sub-group
 - Unapproved minutes from meeting held on 28/2/13
 - Decision summary from meeting held on 28/2/13
 - Formulary version 4.1

Enclosed with agenda
Enclosed with agenda
Updated on website
7. Report from the Shared Care Group
 - Minutes from meeting of 13/2/13
 - Traffic light list version 3.7 Jan 2013
 - Agomelatine Information for primary care - updated
 - Denosumab Information for primary care – updated
 - Cinacalcet Information for primary care
 - Melatonin Shared Care Guideline
 - Erythropoietin Shared Care Guideline
 - Memantine Information for primary care
 - Acetylcholinesterase inhibitors Information for primary care
 - Atomoxetine shared care Guideline

Enclosed with agenda
Updated on website
Enclosed with agenda
Enclosed with agenda
Enclosed with agenda
Enclosed with agenda
Enclosed with agenda
Enclosed with agenda
Enclosed with agenda
8. Report from the Antimicrobial Chemotherapy Sub-group
 - No report due

9. Report from Medicines Management QIPP Sub-group
 - Unapproved minutes from meeting held on 16/1/2013
 Enclosed with agenda
10. NE(NHS)TAG proposal

Email 21/1/13
11. Blood glucose testing guideline/devices

Enclosed with agenda
12. Buccal Midazolam – update on progress (ML)
13. Documents previously circulated by e-mail
 - NECDAG CDF decision summary for Abiraterone for metastatic castration resistant prostate cancer (chemotherapy naive)

Enclosed with agenda
 - NETAG Decision summary notice - Anti-thymocyte globulin for first-line treatment of adult aplastic anaemia

Enclosed with agenda
 - NETAG Decision summary notice - Ulipristal (ellaOne®) for post-coital contraception: Updated appraisal

Enclosed with agenda
 - NETAG Decision summary notice - Aflibercept (Eylea®) for neovascular age-related macular degeneration

Enclosed with agenda
14. APC Guidelines and Statements for review
 - None
15. NICE Technology Appraisals published in January and February
 - TA271: Diabetic macular oedema - fluocinolone acetonide intravitreal implant
 - TA272 : Urothelial tract carcinoma (transitional cell, advanced, metastatic) – vinflunine
 - TA273 : Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)
 - TA 274: Macular oedema(diabetic) – ranibizumab
 - TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban
16. Chairman’s action
 - None taken
17. Any other business
18. Date and time of next meeting:
 Tuesday 14th May 2013
 Room 3, Northumbria House, Unit 7/8 Silver Fox Way, Cobalt Business Park, North Tyneside.
 The meeting will start at 12:30pm